|Day Low/High||8.96 / 9.29|
|52 Wk Low/High||3.60 / 25.77|
The Montrouge, France-based firm unveiled positive topline results from its Phase 3 Realise study of peanut allergy treatment Viaskin Peanut.
The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.
Let's take a look at several stocks that are experiencing unusual volume activity.